White Mark Andrew 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Feb 21, 2024
Insider Transaction Report
Form 4
White Mark Andrew
Chief Medical Officer
Transactions
- Award
Common Stock
2024-02-16+11,096→ 87,758 total - Award
Stock Option (Right to Buy)
2024-02-16+32,727→ 32,727 totalExercise: $30.01Exp: 2034-02-16→ Common Stock (32,727 underlying)
Footnotes (2)
- [F1]Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.
- [F2]This option represents a right to purchase a total of 32,727 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.